<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163837</url>
  </required_header>
  <id_info>
    <org_study_id>AK/14-02-14/4343</org_study_id>
    <nct_id>NCT02163837</nct_id>
  </id_info>
  <brief_title>Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic encephalopathy is responsible for sleep disturbances and daytime sleepiness. The
      purpose of our study is to assess sleep quality, quantity, sleep schemes and physical
      activity in patients suffering from HE, before and after a 2 weeks treatment with rifaximine,
      which is currently given to lower blood ammoniac levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome related to chronic/acute
      hepatic failure. Sleep architecture is disturbed in this syndrome, and patients complain
      mainly of excessive daytime sleepiness and sleep disturbances. Hypothesis to explain these
      symptoms is, among others, disturbed melatonin metabolism. Few studies have been conducted in
      order to study sleep disorders during HE, and effect of treatment is unknown. Recently,
      rifaximine, an oral broad spectrum antibiotic, have been proved to decrease ammoniac
      production in patients with HE. The purpose of our study is to assess sleep quality,
      quantity, sleep schemes and physical activity in patients suffering from HE, before and after
      a 2 weeks treatment with rifaximine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sleep quality</measure>
    <time_frame>2 weeks</time_frame>
    <description>sleep efficiency, percentage slow wave sleep and REM sleep assessed by 24-h polysomnography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sleep schedules</measure>
    <time_frame>2 weeks</time_frame>
    <description>assessed by actigraphy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life</measure>
    <time_frame>2 weeks</time_frame>
    <description>assessed by SF-36 questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>sleep quality</measure>
    <time_frame>2 weeks</time_frame>
    <description>assessed by actigraphy</description>
  </other_outcome>
  <other_outcome>
    <measure>physical activity</measure>
    <time_frame>2 weeks</time_frame>
    <description>assessed by actigraphy</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>rifaximine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifaximine</intervention_name>
    <arm_group_label>rifaximine</arm_group_label>
    <other_name>Targaxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18y hepatic encephalopathy: positive Conn score

        Exclusion Criteria:

          -  &lt;18y pregnancy inability to fulfil questionnaires acute infection unstable clinical
             condition bone or articular disease resulting in significant disability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Bruyneel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU St Pierre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU St Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Saint Pierre</investigator_affiliation>
    <investigator_full_name>Marie Bruyneel</investigator_full_name>
    <investigator_title>Chef de clinique</investigator_title>
  </responsible_party>
  <keyword>sleep quality</keyword>
  <keyword>physical activity</keyword>
  <keyword>daytime sleepiness</keyword>
  <keyword>actigraphy</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 8, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

